COIOSDeep risk insights through multi-disciplinary research across the globe
man in black jacket walking on sidewalk during daytime
Item new Peer-reviewed Added

HPV-cytology co-testing is not cost-effective in Korean cervical cancer screening

HPV-cytology co-testing cost 100.5 to 118.4 million won per QALY over biennial cytology, 3.4 to 3.9 times Korea's threshold.

A Markov model compared no screening, cytology and HPV-cytology co-testing across 30 strategies in Korean women aged 20 and over. Biennial cytology cost 1.8 million won per QALY versus no screening, against a 30 million won threshold. Only 4 of 26 co-testing strategies were on the efficiency frontier, none of them cost-effective. Against biennial cytology, they cost 100.5 to 118.4 million won per QALY. Biennial cytology was optimal in 99.6% of probabilistic simulations. The results are modelled estimates, calibrated to registry incidence and tied to current Korean prices.

Why it is interesting: Even the most efficient co-testing strategy cost over three times Korea's threshold per QALY gained. The model also names the HPV test price at which that strategy's verdict would change.

Source
Journal of Gynecologic Oncology, 20 November 2026
DOI
10.3802/jgo.2027.38.e45
Type
Peer-reviewed article
Design
Markov model cost-utility analysis of 30 cervical screening strategies, women aged 20+, lifetime horizon, Korean healthcare system perspective, calibrated to Korea Central Cancer Registry incidence
Verdict
New finding
Driver
Value in health
Driver
Cancer

Other drivers in Data, models and systems